R. Nolan Townsend, Sandi See Tai, MD, And Kim G. Johnson, MD, On Gene Therapy For APOE4 Homozygous Alzheimer Disease
At ctad 2024, r. Nolan townsend, chief executive officer at lexeo, coauthor sandi see tai, md, chief development officer at lexeo, and lead author kim g. Sandi see tai, md, joined lexeo in 2023. Prior to lexeo, dr. See tai was vp & development head for rare disease at pfizer where she was responsible for setting the rare disease.
“lx1001 is the lead program in our alzheimer’s disease gene therapy portfolio. These encouraging data support our unique approach to target the genetics of alzheimer’s. Risk for alzheimer disease (ad) is known to be strongly associated with apolipoprotein e (apoe) polymorphisms. research demonstrates that people homozygous. Johnson k, kaplitt m, kaminsky s, et al. Peripheral expression of apoe isoforms alters plasma proteomes. To identify potential blood factors mediating the apoe isoform effects on cerebrovasculature and brain.